Poster

RNA-seq, ATAC-seq, and CRISPR Screening: Powering CAR T-Cell Research

About the Poster

Chimeric Antigen Receptor T-cell (CAR-T) approaches show great promise for therapeutic applications but are limited by cell exhaustion, an effect which reduces T-cell effectiveness against blood disorders. For the advancement of research in immune system modulation, CD Genomics offers professional services in RNA sequencing (RNA-seq), assay for transposase- accessible chromatin using sequencing (ATAC-seq), and CRISPR screening. Our advanced sequencing and bioinformatics solutions resolve challenges in chromatin accessibility, functional genomics, and the study of gene expression. This provides reliable insights needed to improve intervention strategies.

In this study, CD Genomics’ multi-omics platforms helped discover interleukin-4 (IL-4) as an important regulator of CART cell exhaustion. Our RNA-seq and ATAC-seq services revealed the transcriptional and epigenetic changes caused by IL-4, and CRISPR screening identified IL-4 signaling as a key pathway leading to CART cell dysfunction. These findings demonstrate how CD Genomics’ integrated solutions enable a greater understanding of CAR-T cell behavior, helping to develop methods for improving therapeutic potential.

For more information about our services:

Download the Poster

* Name:
* Email Address:
* Verification code:
Verification code

CD Genomics needs the contact information you provide to us in order to contact you about our products and services and other content that may be of interest to you.

By clicking below, you consent to the storage and processing of the personal information submitted above by CD Genomcis to provide the content you have requested.

For any other type of support, feel free to contact us
1-631-338-8059 |